Cargando…
Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration
PURPOSE: Real-world data give different information on health-care delivery compared with randomised controlled trials. We aimed to evaluate the appropriateness of possible quality standards for intersite comparisons of outcomes of providing Aflibercept for neovascular age-related macular degenerati...
Autores principales: | Talks, J S, James, P, Sivaprasad, S, Johnston, R L, McKibbin, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684460/ https://www.ncbi.nlm.nih.gov/pubmed/28643799 http://dx.doi.org/10.1038/eye.2017.86 |
Ejemplares similares
-
A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
por: Hykin, Philip, et al.
Publicado: (2016) -
A Multi-Modal AI-Driven Cohort Selection Tool to Predict Suboptimal Non-Responders to Aflibercept Loading-Phase for Neovascular Age-Related Macular Degeneration: PRECISE Study Report 1
por: Chorev, Michal, et al.
Publicado: (2023) -
Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel
por: McKibbin, M, et al.
Publicado: (2015) -
The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022) -
Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)